Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
V503 (9-Valent HPV Vaccine) vs GARDASIL in Chinese Women 20 to 45 Years of Age
NCT03998254Phase 3Active, not recruiting
- Sponsor
- Merck & Co.
- Start
- Jun 2019
- Primary completion
- Mar 2028
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of recombinant human papillomavirus 9-valent vaccine in human papillomavirus infection (2 arms), sponsored by Merck & Co. Primary endpoints: Combined Incidence of HPV 31-, 33-, 45-, 52-, and 58-related 12-month Persistent Infection, Geometric Mean Titers to HPV Types 6, 11, 16, and 18 Antibodies at Month 7 and 4 more. Started Jun 2019; status: active, not recruiting.
02
Drugs
recombinant human papillomavirus 9-valent vaccine
03
Conditions
human papillomavirus infection
Beyond the preview
Go deeper on NCT03998254.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03998254.